Journal
AMERICAN JOURNAL OF OPHTHALMOLOGY
Volume 136, Issue 1, Pages 194-196Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0002-9394(03)00101-6
Keywords
-
Categories
Ask authors/readers for more resources
PURPOSE: To test the efficacy of the novel vascular endothelial growth factor (VEGF) receptor inhibitor SU5416, in a case of refractory von Hippel-Lindau (VHL) retinal hemangioblastoma (RHB). DESIGN: Interventional case report. METHODS: Patient included in a multicenter phase II trial. A 30-year,old woman presenting with VHL disease and multiple RHB on her only eye, refractory to conventional treatments, had decreased visual acuity due to cystoid macular edema (CME). SU5416 was administered intravenously for 7 months. Best-corrected visual acuity (BCVA) and macular thickness were measured by optical coherence tomography. RESULTS: Under treatment, the size of the RHB did not change, but CME improved significantly. Best-corrected visual acuity rose from 20/40 to 20/25. However, CME recurred after the end of the treatment. Conclusion: The VEGF receptor inhibitor SU5416 failed to reduce the size of RHB but was very effective for the associated CME. (C) 2003 by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available